Revolution Medicines to Participate in April 2025 Investor Conferences
Provided By GlobeNewswire
Last update: Mar 31, 2025
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences.
Read more at globenewswire.com
